YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023

GAITHERSBURG,Md.,Aug. 10,2023 --YS Biopharma Co.,Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"),a global biopharmaceutical company dedicated to discovering,developing,manufacturing,and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer,today announced that it plans to release its financial results for the first quarter endedJune 30,2023,after the U.S. market closes onTuesday,August 15,2023.

The Company's management will hold an earnings conference call at8:00 P.M. Eastern Time on Tuesday,2023 to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free: 1-888-346-8982

International: 1-412-902-4272

Mainland China Toll Free: 4001-201203

Canada Toll Free: 1-855-669-9657

Hong Kong: 852-301-84992

Upon dialing-in,participants should ask to be joined into the YS Biopharma Co.,Ltd. call.

The replay will be accessible throughAugust 22,2023by dialing the following numbers:

United States Toll Free: 1-877-344-7529

International: 1-412-317-0088

Canada Toll Free: 855-669-9658

Access Code: 8167733

A live and archived webcast of the conference call will also be available at the Company's investor relations website at https://investor.ysbiopharm.com/.

About YS Biopharma

YSBiopharmais a global biopharmaceutical company dedicated to discovering,and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA®immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies,Coronavirus,Hepatitis B,Influenza,Shingles,and other virus infections. YSBiopharmaoperates inChina,the United States,Singapore,andthe Philippines,and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information,please visitinvestor.ysbiopharm.com.

Investor Relations Contact

Robin Yang

Partner,ICR,LLC

Tel: +1 (212) 537-4035

Email:YSBiopharma.IR@icrinc.com

Alyssa Li

Director of Investor Relations

Email: ir@yishengbio.com